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Abstract
The deubiquitinase OTULIN removes methionine-1 (M1)-linked
polyubiquitin signals conjugated by the linear ubiquitin chain
assembly complex (LUBAC) and is critical for preventing TNF-driven
inflammation in OTULIN-related autoinflammatory syndrome
(ORAS). Five ORAS patients have been reported, but how dysregu-
lated M1-linked polyubiquitin signalling causes their symptoms is
unclear. Here, we report a new case of ORAS in which an OTULIN-
Gly281Arg mutation leads to reduced activity and stability in vitro
and in cells. In contrast to OTULIN-deficient monocytes, in which
TNF signalling and NF-jB activation are increased, loss of OTULIN
in patient-derived fibroblasts leads to a reduction in LUBAC levels
and an impaired response to TNF. Interestingly, both patient-
derived fibroblasts and OTULIN-deficient monocytes are sensitised
to certain types of TNF-induced death, and apoptotic cells are
evident in ORAS patient skin lesions. Remarkably, haematopoietic
stem cell transplantation leads to complete resolution of
inflammatory symptoms, including fevers, panniculitis and diar-
rhoea. Therefore, haematopoietic cells are necessary for clinical
manifestation of ORAS. Together, our data suggest that ORAS
pathogenesis involves hyper-inflammatory immune cells and TNF-
induced death of both leukocytes and non-haematopoietic cells.
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Introduction
Timely activation and resolution of the innate immune response is
essential for tissue homeostasis and host defence, and dysregulation
of this response may cause autoinflammation (Nathan & Ding, 2010).
Autoinflammatory diseases are a heterogeneous group of disorders
characterised by spontaneous development of episodic or chronic
inflammation in the absence of inflammatory provocation. Causative
mutations have been identified in more than 25 genes, most of which
regulate cytokine signalling, e.g. interleukin-1 (IL-1), type I interferon,
or tumour necrosis factor (TNF) signalling, or activation of nuclear
factor-jB (NF-jB) transcription factors (Manthiram et al, 2017).
Key regulatory mechanisms in innate immune signalling rely on
protein ubiquitination, which is a versatile post-translational modifi-
cation that regulates virtually every aspect of cellular homeostasis
(Komander & Rape, 2012). Ubiquitin (Ub) mediates most of its cellu-
lar functions through structurally and functionally distinct polyUb
signals (Komander & Rape, 2012; Swatek & Komander, 2016). These
polyUb chains can be linked via one of the seven Lys (K) residues in
Ub (e.g. K48-linked chains) or via Ub Met1 (M1), forming M1-linked
(also known as linear) chains (Swatek & Komander, 2016).
Ubiquitin chains regulate activation of NF-jB transcription
factors to control inflammation and immunity (Bonizzi & Karin,
2004; Jiang & Chen, 2012; Etzioni et al, 2017). K48-linked chains
mediate timed degradation of the inhibitor of jB (IjB) proteins
while non-degradative chains, including K63- and M1-linked chains,
serve as recruitment and activation platforms in signalling
complexes formed after engagement of pattern recognition receptors
(PRRs) and cytokine receptors, e.g. TNF receptor-1 (TNF-R1).
Receptor stimulation, for example of TNF-R1, triggers assembly of
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multi-protein receptor signalling complexes (RSCs) that include a
host of E3 Ub ligases, including TNF receptor-associated factors
(TRAFs), inhibitor of apoptosis proteins (IAPs) and the linear Ub
chain assembly complex (LUBAC). These generate K63- and M1-
linked Ub chains to facilitate the recruitment of the TGFb-activated
kinase 1 (TAK1) and IjB kinase (IKK) complexes, respectively
(Jiang & Chen, 2012). K63 and M1 Ub linkages can occur in the
same Ub polymers (Emmerich et al, 2013), facilitating TAK1 and
IKK co-localisation and cross-activation (reviewed in Hrdinka &
Gyrd-Hansen 2017).
M1-linked Ub chains are conjugated by LUBAC, which consists
of the catalytic subunit HOIP and the adaptors and co-activators
HOIL-1 and SHARPIN (Kirisako et al, 2006; Gerlach et al, 2011;
Ikeda et al, 2011; Tokunaga et al, 2011). LUBAC exclusively gener-
ates M1-linked Ub chains (Kirisako et al, 2006; Stieglitz et al, 2013)
and is recruited in a Ub-dependent manner to many receptors of the
immune system, including TNF-R1, IL-1 receptor (IL-1R), CD40,
TLRs and NOD2, where it ubiquitinates a host of substrates, includ-
ing RIPK1, RIPK2, MyD88, IRAKs and NEMO directly or on pre-
existing chains (Hrdinka & Gyrd-Hansen, 2017).
Functionally, formation of RSCs and activation of the Ub- and
kinase-dependent signalling cascades leads to activation of
NF-jB transcription factors and pro-inflammatory transcriptional
programmes (Jiang & Chen, 2012). However, for TNF-R1, it can also
lead to cell death via formation of a TRADD-, FADD-, RIPK1/3- and
caspase-8-containing death-inducing complex, complex-II (Fuchs &
Steller, 2015; Kupka et al, 2016b). Recent research has shown that
M1-linked Ub chains are key in determining the fate of a cell upon
TNF stimulation. In the absence of LUBAC, TNF-mediated signalling
is shifted from NF-jB activation towards induction of cell death via
complex-II (Haas et al, 2009; Tokunaga et al, 2009; Gerlach et al,
2011; Ikeda et al, 2011; Peltzer et al, 2014, 2018). Mouse experi-
ments have shown that the resulting TNF-induced cell death can be
highly inflammatory as genetic ablation of LUBAC components
leads to multi-organ inflammation (HogenEsch et al, 1993; Seymour
et al, 2007; Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al,
2011), in large part caused by TNF-induced cell death (Kumari et al,
2014; Rickard et al, 2014). Importantly, homozygous mutations in
the LUBAC components HOIP and HOIL-1 have been identified in
patients suffering from chronic autoinflammatory syndromes (Bois-
son et al, 2012, 2015).
Deubiquitinases (DUBs) are proteases that cleave Ub modifica-
tions and functionally revert Ub signalling. Several DUBs, including
A20 and CYLD, act as negative regulators of NF-jB signalling to
balance activation and ensure resolution of inflammation (Harhaj &
Dixit, 2012). OTULIN (OTU family deubiquitinase with linear Ub
specificity, also known as FAM105B or Gumby) is the only DUB
known to specifically cleave M1 linkages (Keusekotten et al, 2013;
Rivkin et al, 2013). Several studies have shown that OTULIN binds
directly to the LUBAC subunit HOIP (Elliott et al, 2014; Schaeffer
et al, 2014; Takiuchi et al, 2014). In the absence of OTULIN, M1-
linked Ub chains accumulate in cells and receptor signalling
complexes, enhancing NF-jB activation in response to stimulation
of TNF-R1 and NOD2 (Fiil et al, 2013; Keusekotten et al, 2013;
Rivkin et al, 2013; Draber et al, 2015; Damgaard et al, 2016;
Hrdinka et al, 2016; van Wijk et al, 2017). Interestingly, similar to
LUBAC components, homozygous mutations in OTULIN were
recently found to cause autoinflammation in humans (Damgaard
et al, 2016; Zhou et al, 2016), showing that excessive M1-linked Ub
signalling can be harmful. OTULIN-related autoinflammatory
syndrome (ORAS) (also known as otulipenia or autoinflammation,
panniculitis and dermatosis syndrome (AIPDS); OMIM ID: 617099)
is a potentially fatal, TNF-driven autoinflammatory disease charac-
terised by sterile systemic inflammation, recurrent high fevers,
panniculitis, diarrhoea, arthritis and general failure to thrive
(Damgaard et al, 2016; Zhou et al, 2016). Key features of ORAS are
recapitulated in OTULIN-deficient mice (Damgaard et al, 2016).
However, the cellular defects underlying the development of
inflammation in ORAS remain unclear.
Here, we report a new case of ORAS identified by whole-exome
sequencing of a patient with neonatal-onset, severe inflammatory
symptoms. Primary fibroblast cultures from this patient reveal a
surprising phenotype of deregulated M1-linked Ub signalling,
whereby OTULIN loss coincides with LUBAC downregulation to
prevent intrinsic NF-jB activation. In contrast, OTULIN-deficient
myeloid cells are hyper-inflammatory and spontaneously activate
NF-jB and secrete TNF. Both cell types, however, are sensitised to
cell death in response to TNF. Importantly, we find that
haematopoietic stem cell transplantation (HSCT) leads to complete
resolution of all inflammatory symptoms associated with ORAS.
This shows that haematopoietic cells are crucial for the clinical
manifestation of ORAS and indicates HSCT could be are curative
treatment for the disease.
Results
Inflammatory symptoms in a patient with homozygous
OTULIN mutations
A female patient of Arab origin (patient III.2), the second of three
children born to first-degree related parents (her grandfathers are
identical twins; Fig 1A), developed severe inflammatory symptoms
shortly after birth. From the age of 3 days, she developed severe
idiopathic, systemic inflammation and had recurrent episodes of
high fever in combination with widespread panniculitis (Fig 1B and
Appendix Clinical Description). At the age of 7 months, her symp-
toms included high fevers, diarrhoea and panniculitis, and she was
cachectic, weighing 3.4 kg (< 3rd percentile; WHO Multicentre
Growth Reference Study Group, 2006) and had severe splenomegaly
and bilateral cataracts. Laboratory evaluation revealed elevated
acute phase proteins, including C-reactive protein (CRP) and
ferritin, elevated IL-6 and soluble IL-2 receptor (sIL-2R) in serum,
severe anaemia, and leukocytosis with significant monocytosis in
the absence of any evidence of infection (Fig 1B and Appendix Clini-
cal Description).
The consanguineous relations in the family (Fig 1A) indicated
that patient III.2 suffered from an autosomal recessive disorder.
Genetic testing excluded Mediterranean fever and chronic atypical
neutrophilic dermatosis with lipodystrophy and elevated tempera-
ture (CANDLE) syndrome caused by mutations in MEFV and
PSMB8, respectively. Whole-exome sequencing (WES) was
performed to investigate patient III.2’s underlying genetic defect.
Filtering out all common and heterozygous variants, WES
revealed a single, homozygous G-to-A substitution in OTULIN,
c.841G>A; p.Gly281Arg, in patient III.2 (Figs 1A and C and
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Appendix Table S1). The parents of patient III.2 (II.1 and II.2) and
her sister (III.1) were heterozygous for the substitution, whereas her
brother (III.3) did not carry the mutation (Figs 1A and C). WES
revealed no other homozygous or previously annotated pathogenic
variants likely to cause the disease phenotype (Appendix Table S1).
Mutations in OTULIN have recently been described to cause
ORAS, an autosomal recessive autoinflammatory disease (Damgaard
et al, 2016; Zhou et al, 2016). Patient III.2’s symptoms, as well as
the course of disease and effect of treatments (see below,
Appendix Clinical Description), resembled those of other ORAS
patients (Damgaard et al, 2016; Zhou et al, 2016). Hence, patient
III.2 was diagnosed with ORAS.
Mutation of Gly281 to Arg reduces OTULIN’s activity towards
M1-linked Ub by unfolding the substrate-binding site
To date, three different mutations in OTULIN have been reported in
families with patients affected by ORAS. In one family, a single
nucleotide deletion introduces a premature stop codon,
Gly174Aspfs*2, leading to deletion of roughly two-thirds of the cata-
lytic OTU domain (Zhou et al, 2016) and thus likely a complete loss of
function although the N-terminal fragment may be present in cells.
Hypomorphic Leu272Pro and Tyr244Cys missense mutations were
identified in two other families (Damgaard et al, 2016; Zhou et al,
2016). Leu272 is located in the Ub-binding pocket in the OTU domain
and the mutation to Pro impairs M1-linked diUb binding, catalytic effi-
ciency and stability of OTULIN (Damgaard et al, 2016). Tyr244 is not
found or predicted to make any contacts to Ub or be involved in catal-
ysis (Keusekotten et al, 2013), and the main effect of the Tyr244Cys
mutation might be reduced protein stability (Zhou et al, 2016).
Similar to Leu272 and Tyr244, Gly281 is also located in the OTU
domain (Keusekotten et al, 2013). Gly281 is evolutionarily conserved
and located in a loop between helices a11 and a12 (Fig EV1A;
Keusekotten et al, 2013). Together with His282 and Thr283, Gly281
forms part of the Ub-binding site and makes direct contacts to the
proximal Ub of M1-linked diUb bound across the active site (Figs 2A,
centre panel and EV1A; Keusekotten et al, 2013). While Gly281 is in
an important region, the effect of the mutation to Arg is difficult to
predict. To understand the pathogenicity of the Gly281Arg mutation
on OTULIN, we crystallised OTULIN’s catalytic domain (OTULINcat,
aa 80–352) containing the Gly281Arg ORAS mutation (OTULIN-
catG281R) and determined its structure to 1.8 A˚ resolution (Figs 2A
and Appendix Table S2). Overall, the structure showed that OTULIN-
catG281R adopted an OTU fold similar to OTULINcatWT (Keusekotten
et al, 2013) without any major perturbations (Fig 2A). However,
comparing the structure of OTULINcatG281R with the previously
solved structure of OTULINcat in complex with M1-linked diUb
(Keusekotten et al, 2013) showed that the Gly281Arg mutation partly
unfolds the substrate-binding site (Fig 2A, right panel). The intro-
duced Arg side chain can no longer fit into the narrow pocket
between helices a3 and a9 thereby flipping the Gly281-containing
loop out of its normal binding groove (Figs 2A and B; Keusekotten
et al, 2013). In the mutant protein, the loop has increased flexibility,
as represented by the high crystallographic B-factor distribution
across the loop compared to other regions within the OTU domain
(Fig EV1B) and also evidenced by lack of interpretable electron
density for the side chains of Val280, mutated Arg281 and His282
(Fig EV1C). The new conformation of the Gly281-containing loop
indicated that His282 and Thr283 would clash with M1-linked diUb
at the binding site and prevent substrate binding (Fig 2B).
We probed the binding of M1-linked diUb to catalytically inactive
OTULINC129A or OTULINC129A/G281R. As indicated from the structure,
the Gly281Arg mutation strongly reduced binding of M1-linked diUb
to OTULIN and the dissociation constant (KD) of OTULIN
C129A/G281R
and M1-linked diUb was 9.3 lM compared with 85 nM in
OTULINC129A (Fig 2C).
The reduced substrate binding by OTULING281R was also














































Figure 1. Mutations in OTULIN in a new case of OTULIN-related autoinflammatory syndrome (ORAS).
A Segregation of the inflammatory symptoms (filled symbols) and the c.841G>A substitution in OTULIN in the affected kindred. ○, females; □, males; double lines,
consanguineous relationship. Probands I.2 and I.3 are monozygotic twins. Roman numerals indicate generations.
B Schematic representation of the symptoms and clinical presentation of patient III.2.
C OTULIN DNA sequence chromatograms showing the homozygous single base substitution (c.841G>A, p.Gly281Arg, arrowhead). Data are representative to two
independent experiments.
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active towards M1-linked tetraUb compared with OTULINWT
(Fig 2D). At a 5 nM concentration, OTULINWT cleaved ~50% of the
M1-linked tetraUb intro tri-, di- and mono-Ub within 5 min and all
tetraUb was processed at 15 min. In contrast, between 100 nM and
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Figure 2. Mutation of Gly281 to Arg unfolds OTULIN’s substrate-binding site and reduces its catalytic activity.
A Overall structure of OTULING281R (left, PDB: 6I9C) and OTULINC129A bound to M1-linked diUb (middle, PDB: 3ZNZ; Keusekotten et al, 2013) and a superimposition of
the two structures (right). The Ca positions of Gly281/Arg281 are shown as spheres.
B Close-up view of the M1-linked Ub-binding site from OTULING281R (light blue) and OTULIN’s catalytic domain (blue) with M1-linked diUb bound (proximal Ub,
orange; distal Ub, red) showing a clash between proximal Ub and His282 upon G281R mutation (arrow).
C Affinity measurements by fluorescence polarisation (FP) with recombinant catalytically inactive OTULINC129A or OTULINC129A/G281R and FlAsH-labelled M1-linked diUb.
Data represent mean  SD of one experiment performed in technical triplicate. Data are representative of three independent experiments. a.u., arbitrary units. KD,
dissociation constant.
D M1-linked tetraUb hydrolysis by recombinant OTULINWT and OTULING281R using the indicated OTULIN concentrations and visualised on silver-stained SDS–PAGE.
Data are representative of three independent experiments.
E First derivative of tryptophan fluorescence upon thermal unfolding of recombinant OTULINcatWT and OTULINcatG281R (1.0 mg/ml) measured by nanodifferential
scanning fluorimetry (nano-DSF). Apparent melting temperatures (Tm) are indicated (dashed lines). Data are representative to two independent experiments.
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In addition to reduced Ub binding and activity, the Gly281Arg
mutation caused a considerable intrinsic destabilisation of OTULIN.
Monitoring protein unfolding over a thermal gradient, we observed
that the melting temperature (Tm) was reduced from 56.5°C for
OTULINWT to 50.9°C for OTULING281R (Figs 2E and EV1D). This
intrinsic loss of stability indicates a defect in folding of the mutant.
Such defects can be exacerbated in cells where partially damaged or
unfolded proteins trigger protein quality control mechanisms,
including protein degradation.
M1-linked Ub accumulation and destabilisation of OTULING281R
and LUBAC in patient fibroblasts
The cellular defects underlying the development of inflammation in
ORAS are unclear. To study how OTULIN mutations impact on non-
haematopoietic cells and how these cells may contribute to the clini-
cal aspects of ORAS, e.g. panniculitis, we established a primary
dermal fibroblast culture from patient III.2. Surprisingly, immuno-
blot analysis showed that OTULING281R was virtually undetectable
in the patient cells (Fig 3A), suggesting that the partial unfolding of
OTULING281R observed in vitro (Fig 2E) indeed destabilises the
protein. The Gly281Arg mutation did not affect detection of OTULIN
by the antibodies used in this study, which both recognise
OTULIN’s N terminus (Fig EV2A), supporting the notion that
OTULING281R is destabilised in cells. Treatment with the proteasome
inhibitor MG132 substantially increased OTULING281R levels
(Fig 3B), and OTULIN transcript levels remained similar between
healthy control and ORAS fibroblasts (Fig EV2B), strongly indicat-
ing that the reduced OTULING281R level is caused by proteasomal
degradation.
Interestingly, we observed a substantial concomitant destabilisa-
tion of the LUBAC components HOIP and SHARPIN, whereas HOIL-
1 remained largely stable except for a reduction in the level of a
slower-migrating form (HOIL-1L) (Fig 3A). We have previously
reported a similar loss of LUBAC in murine B and T cells (Damgaard
et al, 2016), and we also observed a loss of LUBAC in mouse
embryonic fibroblasts (MEFs) with induced OTULIN deletion
(Fig EV2C), showing this phenomenon is not restricted to human
fibroblasts. Like for murine T and B cells (Damgaard et al, 2016),
transcript levels of HOIP (also known as RNF31), HOIL-1 (also
known as RBCK1) and SHARPIN were largely unaltered between
OTULING281R fibroblasts and controls (Fig EV2B) and inhibition of
autophagosomal degradation could not increase LUBAC protein
levels (Fig EV2D). Instead, we found that HOIP was polyubiquiti-
nated in the OTULING281R fibroblasts (Fig EV2E) and that HOIP
levels could be rescued almost completely by proteasomal inhibition
(Fig 3B), consistent with proteasome-mediated degradation of
LUBAC, particularly HOIP, in the absence of OTULIN in the patient
fibroblasts.
To assess how the reduction in OTULIN, HOIP and SHARPIN
levels in OTULING281R fibroblast impacted the Ub system and the
cellular composition of Ub chain types, we used a non-selective
tandem Ub-binding entity (TUBE; Hjerpe et al, 2009) to purify
polyUb chains from cells in a non-linkage-selective manner
(Fig 3C). The polyUb chains purified by the TUBE were analysed by
absolute quantification (AQUA) tandem mass spectrometry (MS/
MS; Kirkpatrick et al, 2006; Fig 3C). K6, K48 and K63 linkages
combined comprised ~80–85% of the cellular polyUb chains and did
not change, while K27, K29 and K33 linkages were undetectable or
unquantifiable in the OTULING281R and control fibroblasts (Figs 3D
and EV2F and G). Curiously, we noted a reduction in K11 linkages
from ~19% in healthy control fibroblasts to ~10% in OTULING281R
cells (Figs 3D and EV2F and G). Immunoblotting showed no appar-
ent overall differences in the total levels of Ub conjugates or free Ub
in whole-cell lysates between the patient fibroblasts and healthy
control cells (Fig 3E).
Strikingly, despite the reduction in LUBAC levels, the AQUA-MS/
MS analysis revealed a considerable increase in M1-linked Ub
chains from ~0.5% in healthy controls to ~3.5% in OTULING281R
fibroblasts (Figs 3D and EV2F and G). This implies that the remain-
ing LUBAC is still active and may function unantagonised. The
increase in cellular M1 Ub levels, however, was hardly detectable
by immunoblotting, and only a very faint increase in the high
molecular weight smear was observed in the OTULING281R fibrob-
lasts (Fig 3E). This indicates that the increase in M1 linkages might
be relatively low compared to the levels observed in OTULIN-defi-
cient cells that retain LUBAC expression (Draber et al, 2015;
Damgaard et al, 2016; van Wijk et al, 2017). Consistently,
OTULING281R fibroblasts exhibited no appreciable signs of sponta-
neous p65/RelA phosphorylation or IjBa degradation (Fig 3F and
G). This suggests that, in the absence of OTULIN, LUBAC is down-
regulated via proteasomal degradation in the patient fibroblasts,
potentially to reduce the levels of M1-linked Ub and prevent intrin-
sic activation of NF-jB signalling.
Signalling from the TNF-RSC is impaired in
OTULING281R fibroblasts
Decreased OTULIN function increases M1-linked Ub conjugation
and NF-jB activation in response to TNF stimulation in LUBAC-
proficient cells (Fiil et al, 2013; Keusekotten et al, 2013; Damgaard
et al, 2016; Hrdinka et al, 2016). Yet, it is unknown how ORAS cells
with concomitant reduction of HOIP and SHARPIN levels respond
to TNF-R1 engagement. We treated the primary OTULING281R
patient fibroblasts with TNF and analysed NF-jB and MAP kinase
activation by immunoblotting. Interestingly, in contrast to other
OTULIN-deficient cells or cells with RNAi-mediated knock-down of
OTULIN (Fiil et al, 2013; Keusekotten et al, 2013; Damgaard et al,
2016; Hrdinka et al, 2016), TNF signalling was decreased in
OTULING281R fibroblasts, although not completely abrogated
(Fig 4A–C), similar to the response of LUBAC-deficient cells (Haas
et al, 2009; Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al,
2011; Peltzer et al, 2014). Stimulation with TNF led to decreased
phosphorylation and degradation of IjBa as well as reduced phos-
phorylation of p65/RelA compared with healthy controls (Fig 4A
and C). Similarly, phosphorylation and activation of the MAP
kinases p38 and JNK was impaired in the OTULING281R fibroblasts
(Fig 4B). This correlated with a substantial reduction in IL-8 secre-
tion from the patient cells in response to TNF (Fig 4D), showing
that reduced NF-jB and MAP kinase signalling leads to functional
impairment of innate immune signalling in the ORAS fibroblasts in
response to TNF.
After stimulation of TNF-R1, LUBAC translocates to the TNF-RSC
and conjugates M1-linked Ub chains to multiple components of the
complex (Gerlach et al, 2011; Draber et al, 2015). We immunopre-
cipitated the native TNF-RSC after stimulation with TNF, and indeed
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all three LUBAC components, HOIP, SHARPIN and HOIL-1, together
with high molecular weight M1-linked Ub conjugates, co-precipi-
tated with TNF-R1 from healthy control fibroblasts (Fig 4E).
However, in the OTULING281R fibroblasts, recruitment of LUBAC to
TNF-R1 was strongly reduced and hardly detectable (Fig 4E). Inter-
estingly, also HOIL-1, which remains relatively stable in the patient
fibroblasts, could hardly be detected at TNF-RSC, further confirming
that HOIL-1 and SHARPIN are recruited in a HOIP-dependent
manner (Draber et al, 2015). Consistently, the amount of M1-linked
Ub conjugates, but not total Ub conjugates, at the TNF-RSC was
drastically reduced in the patient cells (Fig 4E). Collectively, this
suggests that the primary effect of OTULIN loss in the patient fibrob-
lasts, namely the degradation of LUBAC components to prevent
intrinsic signalling and autoactivation, results in a secondary effect:
the failure to mount a sufficient LUBAC-dependent response to TNF
stimulation.
NF-jB activation and TNF secretion in human
OTULIN-deficient monocytes
Conditional deletion of OTULIN in myeloid cells recapitulates
many aspects of ORAS in mice (Damgaard et al, 2016). This is
associated with increased NF-jB activation and spontaneous TNF
secretion from OTULIN-deficient BMDMs, which, in contrast to T
cells, B cells, MEFs and ORAS fibroblasts, retain normal LUBAC
levels after loss of OTULIN (Damgaard et al, 2016; Figs 3A and
EV2C). Yet, how human myeloid cells react to loss of OTULIN is
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Figure 3. LUBAC degradation and accumulation of M1-linked Ub in OTULING281R fibroblasts.
A Immunoblot analysis of whole-cell lysates from untreated primary healthy control and patient fibroblasts. Data are representative of three independent
experiments.
B Immunoblot analysis of whole-cell lysates from primary healthy control and patient fibroblasts either left untreated or treated with the proteasome inhibitor
MG132 (10 lM) for 24 h. Data are representative of two independent experiments.
C Schematic representation of the AQUA-MS/MS-based proteomics approach for quantification of cellular Ub linkage composition.
D AQUA-MS/MS data from TUBE-based purification of cellular polyUb conjugates from untreated primary fibroblasts from a healthy control or patient III.2 harbouring
the OTULING281R mutation. K27, K29, linkages could not be detected, and K33 could not be accurately quantified in all samples. Data are representative of two
independent experiments (see Fig EV2F and G).
E, F Immunoblot analysis of whole-cell lysates from untreated primary healthy control or patient fibroblasts. Data are representative of three independent experiments.
G Immunoblot (left) and densitometry (right) analysis of IjBa levels in primary healthy control and patient fibroblasts treated with cycloheximide (CHX) (50 lg/ml) as
indicated. Data are representative of three independent experiments.
Source data are available online for this figure.
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secretion in human THP-1 monocytes with stable, short-hairpin
RNA (shRNA)-mediated knock-down of OTULIN (shOTULIN cells)
compared with cells expressing a non-targeting shRNA (shControl
cell) (Hrdinka et al, 2016). The shOTULIN THP-1 cells showed
substantial reduction in cellular OTULIN levels, although some
OTULIN remained (Fig 5A). Similar to OTULIN-deficient murine
BMDMs, LUBAC remained stable in shOTULIN cells and the levels
of HOIP, HOIL-1 and SHARPIN were indistinguishable from those
of shControl cells (Fig 5A). Importantly, OTULIN deficiency in
THP-1 monocytes led to spontaneous phosphorylation of p65/RelA
(Fig 5A) and drastically increased turnover of IjBa (Fig 5B),
indicative of NF-jB activation in shOTULIN cells. Significantly,
shOTULIN cells spontaneously secreted TNF in the absence of any
stimulus (Fig 5C). This shows that the shOTULIN cells have
increased basal NF-jB activation and spontaneously secrete cytoki-
nes, similar to our previous report for OTULIN-deficient BMDMs
(Damgaard et al, 2016).
As the shOTULIN cells spontaneously secrete TNF, we examined
their signalling after TNF stimulation. In response to TNF, the
shOTULIN cells also exhibited a stronger NF-jB signalling response
(Fig 5D). Immunoblotting revealed increased IjBa phosphorylation
and degradation as well as elevated p65/RelA phosphorylation after
TNF stimulation in the shOTULIN cells compared with shControls
(Figs 5D and E).
This shows that also human OTULIN-deficient myeloid cells have
a TNF-associated hyper-inflammatory phenotype and indicates that
myeloid cells may be fundamentally different from fibroblasts in
their response to loss or reduction of OTULIN function.
OTULIN deficiency sensitises fibroblasts and monocytes to
TNF-induced cell death
Dysregulation of TNF-induced NF-jB activation in various tissues
and cell types can result in inflammation due to increased cell death
(Pasparakis, 2009). The autoinflammatory conditions caused by
LUBAC deficiency are examples of this. SHARPIN-deficient cpdm
(chronic proliferative dermatitis) mice (HogenEsch et al, 1993;
Seymour et al, 2007; Gerlach et al, 2011; Ikeda et al, 2011) and
patients with mutations in HOIP or HOIL-1 (Boisson et al, 2012,
2015, 2015) develop severe autoinflammatory syndromes. LUBAC
destabilisation caused by these genetic alterations impairs TNF
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Figure 4. TNF-induced NF-jB and MAP kinase activation is impaired in OTULING281R fibroblasts due to reduced LUBAC recruitment to the TNF-RSC.
A Immunoblot analysis of IjBa phosphorylation and degradation as well as p65/RelA phosphorylation in healthy control or OTULING281R fibroblasts primary fibroblasts
in response to stimulation with TNF (10 ng/ml). Data are representative of three independent experiments.
B Immunoblot analysis of phosphorylation of the MAP kinases p38 and JNK in healthy control or OTULING281R primary fibroblasts in response to stimulation with TNF
(10 ng/ml). Data are representative of three independent experiments.
C Densitometry analysis of p65/RelA phosphorylation as presented in (A) from three independent experiments.
D ELISA analysis of IL-8 secretion in response to TNF stimulation (10 ng/ml) in healthy control or OTULING281R primary fibroblasts. Bars represent mean  SEM (n = 4).
E Immunoblot analysis of the native TNF-RSC purified by immunoprecipitation from healthy control or OTULING281R primary fibroblasts. Data are representative of
three independent experiments.
Source data are available online for this figure.
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2011; Tokunaga et al, 2011; Boisson et al, 2012, 2015), leading to
TNF-R1-dependent induction of (mainly) TRADD-, FADD- and
caspase-8-dependent apoptosis (Gerlach et al, 2011; Ikeda et al,
2011; Peltzer et al, 2014, 2018), which is the main driver of
inflammation (Kumari et al, 2014; Rickard et al, 2014). Addition-
ally, knock-in mice expressing catalytically inactive OTULINC129A
die mid-gestation (~E10.5) due to aberrant cell death (Heger et al,
2018), similar to HOIP- or HOIL-1-deficient mice (Peltzer et al,
2014, 2018). We tested whether OTULING281R ORAS fibroblasts were
sensitised to TNF-induced cell death. Interestingly, we found that
OTULING281R fibroblasts, despite their reduction in LUBAC levels,
were not sensitive to cell death induced by TNF (Fig 6A) or a range
of other stimuli (Fig EV3A). This is in contrast to LUBAC-deficient
cells (Gerlach et al, 2011; Ikeda et al, 2011; Peltzer et al, 2014,
2018) or cells expressing inactive OTULINC129A (Heger et al, 2018),
which are all sensitive to cell death induced by TNF alone. We
found, however, that the OTULING281R fibroblasts were sensitive to
cell death induced by treatment with TNF in combination with the
protein synthesis inhibitor cycloheximide (CHX; Fig 6A), suggesting
that under certain stress conditions the patient fibroblasts are sensi-
tised to TNF-induced cell death.
TNF-induced cell death may occur either via caspase-dependent
apoptosis or RIPK1 kinase-dependent necroptosis (Fuchs & Steller,
2015). Treatment of the OTULING281R fibroblasts with the general
caspase inhibitor Q-VD-OPh or the RIPK1 kinase inhibitor necro-
statin-1 (Nec-1) showed that caspase inhibition rescued the majority
of the TNF+CHX-induced cell death in the ORAS fibroblasts
(Fig 6B). Nec-1 treatment alone only conferred mild protection
against cell death, but treatment of ORAS fibroblasts with a combi-
nation of Q-VD-OPh and Nec-1 led to an almost complete rescue
(Fig 6B). This shows that the OTULING281R fibroblasts likely die by
apoptosis and to a lesser extent by necroptosis, consistent with the
mode of TNF-induced cell death observed in LUBAC-deficient cells
in culture and in SHARPIN-deficient cpdm mice (Gerlach et al,
2011; Ikeda et al, 2011; Berger et al, 2014; Kumari et al, 2014;
Rickard et al, 2014).
Interestingly, despite their normal LUBAC levels, the shOTULIN
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Figure 5. OTULIN deficiency in human THP-1 monocytes leads to increased NF-jB activation and spontaneous TNF secretion.
A Immunoblot analysis of whole-cell lysate from untreated human THP-1 monocytes with stable expression of a non-targeting control shRNA or and shRNA targeting
OTULIN. Data are representative of two independent experiments.
B Immunoblot (left) and densitometry (right) analysis of IjBa levels in shControl and shOTULIN THP-1 cells treated with cycloheximide (CHX) (50 lg/ml) as indicated.
Data are representative of three independent experiments.
C ELISA analysis of spontaneous TNF secretion over 96 h in shControl and shOTULIN THP-1 cells. Data represent mean  SEM (n = 4) and were analysed using the
two-way ANOVA test of statistical significance with Sidak’s correction for multiple comparisons.
D Immunoblot analysis of IjBa phosphorylation and degradation as well as p65/RelA phosphorylation in shControl and shOTULIN THP-1 cells in response to
stimulation with TNF (10 ng/ml). Data are representative of three independent experiments.
E Densitometry analysis of p65/RelA phosphorylation as presented in (D) from three independent experiments.
Source data are available online for this figure.
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but not to cell death by TNF alone (Figs 6C and EV3B), similar to
the OTULING281R fibroblasts. The cell death in shOTULIN cells could
completely be prevented by treatment with Q-VD-Oph, and Nec-1
treatment had no significant effect, neither alone nor in combination
with caspase inhibition (Fig 6D). This is consistent with a recent
report showing that LUBAC, in addition to its pro-survival role at
TNF-R1, also contributes to TNF-induced apoptosis by inducing
cFLIP degradation (Tang et al, 2018).
Inactivation of OTULIN by expression of OTULINC129A in adult
mice has recently been reported to cause systemic inflammation,
which can be prevented by combined ablation of cell death path-
ways by deletion of caspase-8, RIPK3 and RIPK1 (Heger et al, 2018).
Together with the increased cell death we observe in vitro, this
suggests that cell death may contribute to ORAS pathogenesis. We
analysed skin biopsies from ORAS patient III.2, taken at an
inflammatory flare, and healthy control subjects for markers of cell
death. Skin from the ORAS patient showed evidence of prominent
inflammation with diffuse neutrophil infiltration, particularly
around adipocytes, in the dermis and subcutaneous tissues, consis-
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Figure 6. OTULIN deficiency sensitises cells to TNF-induced apoptosis.
A–D Viability of healthy control or OTULING281R primary fibroblasts (A, B) and shControl and shOTULIN THP-1 cells (C, D) after 24 h and 6 h, respectively, of treatment
with TNF (100 ng/ml), CHX (50 lg/ml), Q-VD-OPh (10 lM) and Nec-1 (10 lM) as indicated was analysed using MTT reduction assays. Results were normalised to
untreated samples. Each experiment was performed in duplicate. Bars represent mean  SEM (A, n = 9; B, n = 6; C, n = 8; D, n = 4) and were analysed using the
two-way ANOVA test of statistical significance with Sidak’s correction for multiple comparisons.
E Increased apoptotic cell death in the skin of ORAS patient III.2. Serial sections of normal skin (top panels) and a skin biopsy from patient III.2 taken at an
inflammatory flare (bottom panels) were immunostained for cleaved caspase-3 (centre panels) or analysed by terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) assay (right panels). Arrowheads indicate cleaved caspase-3-positive mesenchymal cells. None of these markers were present in the healthy
control skin. H&E, haematoxylin and eosin. Boxes in H&E panels indicate the areas magnified in the cleaved caspase-3 and TUNEL panels. Scale bars, 100 lm. Data
are representative of stained sections from three healthy controls and one biopsy from ORAS patient III.2.
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This inflammation correlated with the presence of cleaved caspase-
3-positive and TUNEL-positive cells in the dermis and subcutaneous
tissues (Fig 6E), showing that cell death occurs in vivo during ORAS
inflammation. Intriguingly, cleaved caspase-3-positive cells appeared
to be mainly mesenchymal cells, including fibroblasts (Fig 6E, centre
panels, arrowheads), whereas TUNEL-positive cells appeared to be
mainly infiltrating leukocytes (Fig 6E, bottom panels).
These data show that cell death (including apoptosis) occurs in
ORAS and that it may contribute to the TNF-driven pathogenesis of
the disease.
Haematopoietic stem cell transplantation ameliorates ORAS
Previously, we have shown that deletion of OTULIN in all
haematopoietic cell types in mice, or in myeloid cells alone, is suffi-
cient to recapitulate key features of ORAS (Damgaard et al, 2016).
But whether haematopoietic cells are necessary or sufficient to drive
ORAS in humans is unknown. Importantly, we could use the case of
ORAS in patient III.2 to address this retrospectively. As outlined,
patient III.2 developed severe inflammatory symptoms within the
first months of her life and she had a poor response to conventional
anti-inflammatory treatment (Appendix Clinical Description). From
the age of 8 months, she was treated with prednisone and colchicine,
to which she only had a partial response (Fig 7A), similar to previ-
ous reports from ORAS patients (Damgaard et al, 2016; Zhou et al,
2016). At the age of 11 months, the recombinant IL-1 receptor antag-
onist anakinra was added to the treatment regimen without any
improvement of her symptoms. Because of this poor response to
treatment and the impaired pre-transplant performance status of the
patient, HSCT was performed at the age of 17 months (Fig 7A) with
reduced intensity fludarabine-based conditioning that included flu-
darabine (30 mg/m2/day for 6 days), busulphan (3.2 mg/kg/day for
4 days) and thiotepa (10 mg/kg/day for 1 day) together with anti-
thymocyte globulin (ATG) (10 mg/kg). The donor was the patient’s
HLA-matched father. The course of transplantation was uneventful,
and 100% donor chimerism was achieved 17 days after HSCT
(Fig 7B and Appendix Clinical Description). Remarkably, HSCT
resulted in complete resolution of all inflammatory symptoms,
including panniculitis, arthritis and diarrhoea, and the patient expe-
rienced complete clinical remission (Fig 7A and Appendix Clinical
Description). As we and others have found signalling and cell death
defects in OTULIN-deficient non-haematopoietic cells (Figs 3 and 4;
Heger et al, 2018), complete remission after HSCT strikingly shows
that OTULIN deficiency in haematopoietic cells is necessary for clini-
cal manifestation of ORAS including the organ-specific symptoms
panniculitis and diarrhoea (Fig 7D).
Nine months after HSCT, at the age of 26 months, patient III.2
relapsed with fevers, panniculitis and arthritis, albeit with less
severe symptoms than before the transplantation (Fig 7A and C,
and Appendix Clinical Description). The relapse correlated with a
progressive decrease in bone marrow chimerism and regrowth of
patient III.2’s haematopoietic cells (Fig 7B). In mice, bone marrow
chimerism with 50% OTULIN-deficient cells is sufficient to cause
severe systemic ORAS-like inflammation (Damgaard et al, 2016),
indicating that the decrease in chimerism observed in patient III.2
(Fig 7B) is sufficient to cause the relapse.
After the relapse, treatment with prednisone was resumed until
the age of 29 months where patient III.2 started treatment with the
TNF-blocking agent etanercept (soluble TNF receptor fusion protein;
0.4 mg/kg, twice weekly; Fig 7A and Appendix Clinical Descrip-
tion). This led to immediate and complete resolution of her
inflammatory symptoms, and corticosteroid treatment was discon-
tinued. Now, at age ~12 years, patient III.2 is treated with low dose
etanercept (0.8 mg/kg) every 10 days and she remains asymp-
tomatic as long as administration is regular (Fig 7C and
Appendix Clinical Description).
Collectively, these data show that haematopoietic cells are
required for clinical manifestation of ORAS and confirm that TNF is
the driver cytokine for all inflammatory aspects of the disease (Dam-
gaard et al, 2016), adding ORAS to the growing list of TNF-related
pathologies (Kalliolias & Ivashkiv, 2016; Manthiram et al, 2017).
Intriguingly, the dependence on OTULIN-deficient haematopoietic
cells for ORAS implies that myeloid cells are the main drivers of the
TNF-mediated inflammation (Figs 5 and 7D), as OTULIN deficiency
in B or T cells alone in mice does not produce any inflammatory
phenotypes (Damgaard et al, 2016). Moreover, it indicates that cell
death in ORAS might be a key contributing and amplifying result of
TNF-mediated inflammation (Figs 6E and 7D).
Discussion
Here, we report a new case of ORAS caused by homozygous hypo-
morphic c.841G>A; p.Gly281Arg mutations in a patient from a
consanguineous family. To date, only three families (five patients)
with OTULIN mutations and ORAS manifestations had been reported
(Damgaard et al, 2016; Zhou et al, 2016). Our report of a new case of
ORAS caused by a novel Gly281Arg mutation adds a new family and
patient that expands our understanding of the pathogenesis of the
disease, its clinical aspects, as well as its treatment.
Correct regulation of M1-linked Ub conjugation by LUBAC and
hydrolysis by OTULIN is critical to maintain immunehomeostasis in
humans and mice. This is evident from clinical genetic studies
(Boisson et al, 2012, 2015; Damgaard et al, 2016; Zhou et al, 2016)
and numerous mouse studies (reviewed in Hrdinka & Gyrd-Hansen,
2017). Interestingly, the clinical result of mutations in HOIL-1 or
HOIP (i.e. reduced M1-linked Ub conjugation) or in OTULIN (i.e.
reduced M1-linked Ub hydrolysis) is the same: inflammation. Clini-
cally, HOIL-1 and OTULIN deficiency manifests similarly with
neonatal-onset systemic inflammation, recurrent fevers and failure
to thrive (Boisson et al, 2012; Damgaard et al, 2016; Zhou et al,
2016). However, some important differences between these diseases
exist. HOIL-1 deficiency is associated with severe primary immun-
odeficiency, cardiomyopathy and muscle weakness (Boisson et al,
2012; Nilsson et al, 2013; Wang et al, 2013), of which there is no
evidence in ORAS patients (Damgaard et al, 2016; Zhou et al,
2016). In addition, TNF blockade is highly effective in all ORAS
patients reported. Standard immunosuppression (e.g. corticos-
teroids) is, on the other hand, generally ineffective (Damgaard et al,
2016; Zhou et al, 2016). In contrast, corticosteroid treatment is
generally effective in HOIL-1 deficiency whereas anti-TNF treatment
in these patients is not (Boisson et al, 2012). This suggests that the
underlying defects causing these syndromes, while overlapping,
may be different.
OTULIN-related autoinflammatory syndrome patients respond
poorly to standard anti-inflammatory and immunosuppressive
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treatments (Damgaard et al, 2016; Zhou et al, 2016), but their
inflammatory symptoms can be alleviated by neutralisation of TNF
(Damgaard et al, 2016; Zhou et al, 2016). These treatments, however,
have to be regular (and likely lifelong) as omission or delay in
administration can cause inflammation to flare-up (Fig 7C and
Appendix Clinical Description). Currently, there is no cure for ORAS.
C Patient III.2A
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OTULIN-Related Autoinﬂammatory Syndrome (ORAS)
Figure 7. HSCT ameliorates clinical ORAS symptoms in patient III.2.
A Schematic of the timeline of clinical disease in patient III.2 (see Appendix Clinical Description). Arrows indicate therapeutic interventions. d, day; mo, month; yr, year.
B Analysis of the blood cell chimerism in patient III.2 after HSCT. Short terminal repeat (STR) analysis was used to determine the percentage of donor cells in peripheral
blood. Arrow indicates point of relapse.
C Photograph of patient III.2 at age ~10 years at an episode of inflammation caused by delayed etanercept administration. Arrows indicate the erythematous
subcutaneous nodules (panniculitis).
D Model of the cellular effects of OTULIN deficiency in myeloid cells and fibroblasts in ORAS. Hyper-signalling and TNF secretion in myeloid cells as well as TNF-induced
cell death of both haematopoietic cells and cell types with LUBAC downregulation, e.g. dermal fibroblasts, may contribute to the inflammation, pathogenesis and
clinical manifestation of ORAS.
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We provide here the first report of the outcome of HSCT for ORAS.
Remarkably, HSCT led to complete remission of the patient’s severe
ORAS symptoms, including panniculitis, arthritis and diarrhoea,
showing that haematopoietic cells are crucial for manifestation of the
disease. The patient’s unfortunate relapse appears to be due to
regrowth of her haematopoietic cells (Fig 7B). The decreased donor
chimerism is most likely a consequence of the reduced intensity pre-
transplantation conditioning, which may have enabled proliferation of
residual haematopoietic stem cells in the patient, leading to a drop in
donor chimerism and a relapse of inflammatory symptoms. We there-
fore suggest the use of more intense, fully myeloablative conditioning
regimes as preparation for HSCT if such regimes can be tolerated by
the recipients. Despite the patient’s relapse, this case supports further
studies into HSCT as a potential treatment to ameliorate ORAS.
The Gly281Arg mutation identified in this study has a drastic
impact on OTULIN. Not only does it reduce binding of and catalytic
activity towards M1-linked Ub chains, but it also destabilises the
protein such that OTULING281R is hardly detectable in the absence of
proteasome inhibitor in patient fibroblasts. Destabilisation of
OTULIN by ORAS mutations has been described for two other point
mutations, Leu272Pro and Tyr244Cys, as well as the premature stop
mutant Gly174Aspfs*2 (Damgaard et al, 2016; Zhou et al, 2016).
The combination of reduced catalytic activity and very low protein
levels of OTULING281R in cells indicates that the mutation might
cause close to a complete loss of OTULIN function in vivo. The effect
of the Gly281Arg mutation on OTULIN is similar in mechanism to
the Leu272Pro mutation identified in a different ORAS family (Dam-
gaard et al, 2016; Zhou et al, 2016). Collectively, this strongly
suggests that ORAS is a disease of loss or significant reduction of
OTULIN activity and expression.
In cells, we observed a considerable increase in M1 Ub linkages
in the OTULING281R patient fibroblasts, despite the drastically
reduced HOIP and SHARPIN levels. At steady state, the cellular
levels of M1-linked Ub are very low (Figs 3D and EV2F) (Fiil et al,
2013; Keusekotten et al, 2013; Draber et al, 2015), yet they accumu-
late transiently in receptor complexes to facilitate signalling (Fig 4E)
(Gerlach et al, 2011; Emmerich et al, 2013; Fiil et al, 2013;
Keusekotten et al, 2013; Peltzer et al, 2014; Rickard et al, 2014;
Draber et al, 2015; Hrdinka et al, 2016; Kupka et al, 2016a). This
suggests that M1-linked Ub is a potent and highly regulated signal
that is strictly controlled in cells to prevent intrinsic activation or
dysregulation of signalling. In the OTULING281R fibroblasts, we
observed a chronic and global accumulation of M1-linked Ub chains
(Figs 3D and EV2F and G) together with a striking concomitant
reduction in LUBAC levels and no evidence of spontaneous NF-jB
activation (Figs 3A, F and G). This suggests that in certain cell
types, e.g. T and B cells (Damgaard et al, 2016) and fibroblasts
(Figs 3A and EV2C), the potentially uncontrolled M1-linked Ub
accumulation in the absence of OTULIN may function as a “stress”
signal that somehow feeds back and reduces LUBAC activity by
downregulating the level of this complex via the proteasome,
thereby maintaining homeostasis by preventing or reducing intrinsic
activation of inflammatory signalling. However, downregulation of
LUBAC also means that these cells cannot respond appropriately to
external signals, including TNF, which may in turn contribute to
ORAS pathogenesis (Fig 7D, see below).
Different cell types respond differently to loss of OTULIN. In
murine models, LUBAC is stable in OTULIN-deficient myeloid cells,
but not in B and T cells where HOIP and SHARPIN levels are reduced
(Damgaard et al, 2016). Reduction in LUBAC levels, primarily in HOIP
and SHARPIN, has also been reported in fibroblasts from three dif-
ferent ORAS patients (Zhou et al, 2016). Similarly, we observe here
that HOIP and SHARPIN levels are reduced in OTULING281R fibroblasts
while LUBAC remains stable in OTULIN-deficient THP-1 monocytes.
This striking cell type-specific effect on LUBAC suggests that the
phenotype of different cell types upon loss of OTULIN may depend on
their LUBAC status. LUBAC exists, at least, as a trimeric HOIP-HOIL-1-
SHARPIN complex (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga
et al, 2011), but the stoichiometry of components and whether it
varies between cell types is unknown. Specific subpopulations of
LUBAC, e.g. dimeric HOIP-HOIL-1 or HOIP-SHARPIN complexes or
complexes stably associated with other factors such as DUBs, remain
a topic of active investigation. Recently, it was reported that OTULIN
and CYLD, via its adaptor SPATA2, utilise the same mechanism to
interact with HOIP, thereby forming mutually exclusive complexes
(Draber et al, 2015; Elliott et al, 2016). This suggests that distinct
pools of LUBAC-DUB complexes may exist (Hrdinka & Gyrd-Hansen,
2017). The apparently specific downregulation of HOIP and SHARPIN
in ORAS patient fibroblasts (Fig 3A; Zhou et al, 2016) and in T and B
cells (Damgaard et al, 2016) might suggest that OTULIN could be a
part of and/or regulate a distinct HOIP-SHARPIN complex. However,
this needs further investigation. Our data suggest that careful assess-
ment of steady state levels of OTULIN and LUBAC, and possibly
CYLD, is necessary for appropriate interpretation of experiments
involving OTULIN, LUBAC and M1-linked Ub signalling.
OTULING281R fibroblasts are functionally LUBAC-deficient after
TNF stimulation. LUBAC recruitment and M1-linked Ub conjuga-
tion at the TNF-RSC are reduced, accompanied by impaired TNF
signalling, decreased IL-8 secretion and sensitisation to TNF-
induced cell death in the presence of CHX (Fig 4). Interestingly,
OTULIN-deficient THP-1 cells, which are hyper-inflammatory and
hyper-signal in response to TNF (Fig 6), are also sensitive to this
form of cell death, despite their normal levels of LUBAC. These
observations suggest that ORAS may not only be caused by TNF-
induced hyper-signalling and cytokine secretion (Damgaard et al,
2016), but that ORAS pathogenesis may also involve cell death
(Fig 7D). Our analysis of cell death in biopsies from ORAS patient
III.2 supports this notion and provides clear evidence of apoptosis
in the skin of this patient at the time of an inflammatory flare.
This bears resemblance to the dermatitis phenotypes in LUBAC-
deficient mice and the cell death observed in LUBAC-deficient cells
(Kumari et al, 2014; Peltzer et al, 2014, 2018; Rickard et al, 2014;
Taraborrelli et al, 2018). However, in contrast to LUBAC deficiency
where cells are sensitised to cell death induced by TNF alone,
OTULIN-deficient cells need additional perturbation (i.e. CHX)
before they become sensitive to TNF-induced death. This could
suggest that cell death of OTULIN-deficient cells may be a
secondary effect of a “stressed” environment, such as an inflamed
tissue. The dermatitis in SHARPIN-deficient cpdm mice is caused
by cell or tissue intrinsic defects leading to TNF-induced cell death
of keratinocytes (Kumari et al, 2014; Rickard et al, 2014) and it is
not mediated by immune cells as allogeneic BM or splenocyte
transplantations fail to transfer the disease to WT mice (Hogen-
Esch et al, 1993; Rickard et al, 2014). In contrast, OTULIN defi-
ciency in haematopoietic cells is necessary for manifestation of
skin inflammation/panniculitis in ORAS patients as demonstrated
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here by HSCT (Fig 7A–C and Appendix Clinical Description). Yet,
mouse models indicate that OTULIN deficiency in haematopoietic
cells is not sufficient for development of the full spectrum of ORAS
symptoms. Mice with genetic ablation of OTULIN either in all
haematopoietic cell types or specifically in myeloid cells develop
systemic ORAS-like inflammation, but the organ-specific symptoms
that are hallmarks of the human disease (panniculitis, diarrhoea
and arthritis) do not manifest spontaneously in these models
(Damgaard et al, 2016). The full clinical disease in ORAS may
therefore be a “compound” phenotype where hyper-inflammatory,
TNF-secreting haematopoietic (myeloid) cells cause TNF-induced
inflammation and cell death of both non-haematopoietic cells with
LUBAC downregulation, e.g. dermal fibroblasts, and haematopoi-
etic cells (Fig 7D), thereby giving rise the organ-specific hallmark
symptoms panniculitis, diarrhoea and arthritis.
Together, these clinical and experimental data expand our under-
standing of the cellular mechanisms leading to ORAS development
and indicate HSCT as a new potential treatment to ameliorate ORAS.
Materials and Methods
Whole-exome analysis
Exonic sequences from a DNA sample from patient III.2 were
enriched using SureSelect Human All Exon 50 Mb V.5 Kit (Agilent
Technologies, Santa Clara, CA) and sequenced on an Illumina
HiSeq2500 (Illumina, San Diego, CA) with 100-bp paired-end reads.
Data were analysed on the DNAnexus platform (DNAnexus, Inc.,
Mountain View, CA) using default parameters with the human
genome assembly hg19 (GRCh37) as reference. For further details,
see Appendix Supplementary Methods.
Expression and purification of recombinant proteins
OTULIN and TUBE proteins were purified from E. coli as described
in (Elliott et al, 2014) and (Hrdinka et al, 2016), respectively. For
further details, see Appendix Supplementary Methods.
Qualitative DUB assay
Qualitative Ub cleavage assays were performed as previously
described (Keusekotten et al, 2013). For further details, see
Appendix Supplementary Methods.
Protein crystallisation and structure determination
OTULINcatG281R crystals were grown by hanging drop vapour diffu-
sion method and the structure solved by molecular replacement
using PHASER (McCoy et al, 2007) with wild-type OTULINcat (PDB
ID 3ZNV) as the search model. For further details, see Appendix Sup-
plementary Methods.
Binding assays
Fluorescence anisotropy experiments were performed as previously
described (Keusekotten et al, 2013). For further details, see
Appendix Supplementary Methods.
Differential scanning fluorimetry (DSF) thermal
unfolding experiments
Nano-DSF measurements were performed as previously described
(Damgaard et al, 2016). For further details, see Appendix Supple-
mentary Methods.
Cell culture
A primary fibroblast culture from patient III.2 was established
from a skin punch biopsy. Primary fibroblasts were cultured in
Ham’s F-10 nutrient mix + GlutaMAXTM (Life Technologies)
supplemented with 20% iron-supplemented foetal calf serum
(FCS) (#C8056, Sigma) (v/v) and penicillin/streptomycin (Life
Technologies). Human THP-1 monocytes with stable short-hairpin
RNA (shRNA)-mediated knock-down of OTULIN (shOTULIN) or a
non-targeting control (shControl) were a kind gift from Dr. Mads
Gyrd-Hansen (University of Oxford) (Hrdinka et al, 2016). THP-1
cells were cultured undifferentiated in RPMI-1640 + GlutaMAXTM
(Life Technologies) supplemented with 1 mM sodium pyru-
vate (Life Technologies), 10% FCS (Life Technologies) (v/v),
50 lM b-mercaptoethanol and penicillin/streptomycin (Life Tech-
nologies). All cells were kept at 37°C in a humidified atmosphere
at 5% CO2. All cultures were found to be negative for myco-
plasma contamination by regular PCR testing (Young et al,
2010).
Cell stimulations and signalling experiments
Primary fibroblasts or THP-1 cells were treated as indicated in fig-
ures and legends. For signalling experiments, cells were stimulated
with recombinant human TNF (Life Technologies). For proteasomal
inhibition, cells were treated with 10 lM MG132 (Sigma) in DMSO
as indicated. For inhibition of autophagosomal degradation, cells
were treated with 100 nM bafilomycin A1 from Streptomyces griseus
(BafA) (Sigma) in DMSO as indicated. Cells were lysed either
directly in sample buffer (50 mM Tris pH 6.8, 10% glycerol (v/v),
100 mM DTT, 2% SDS (w/v), bromophenol blue), sonicated using
a microtip for 5 s at 30% amplitude on a Vibra-CellTM VC750 (Sonics
& Materials, Inc., Newton, CT) and boiled for 2 min, or lysed in
RIPA buffer (50 mM Tris pH 7.4, 1% NP-40 (v/v), 0.5% deoxy-
cholate (w/v), 0.1% SDS (w/v), 150 mM NaCl, 2 mM EDTA, 5 mM
MgCl2) for 20 min on ice, lysate cleared by centrifugation and
supplemented with 4× sample buffer. For assessment of IjBa stabil-
ity, THP-1 cells were washed in PBS and seeded in 96-well plates in
complete medium ~16 h before they were treated with 50 lg/ml
cycloheximide (CHX; Santa Cruz Biotechnology, Santa Cruz, CA) in
DMSO as indicated. IjBa stability in primary fibroblasts was
assayed by seeding the fibroblasts in 12-well plates 18–24 h prior to
treatment with CHX as indicated. After CHX treatment, all cells were
washed in PBS and lysed in RIPA buffer.
Immunoprecipitation of the TNF-RSC
Immunoprecipitation of the TNF receptor signalling complex (TNF-
RSC) was performed using 100 ng/ml FLAG-tagged TNF (Enzo Life
Sciences, Farmingdale, NY) as previously described (Fiil et al,
2013). For further details, see Appendix Supplementary Methods.
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Purification of endogenous polyUb conjugates by
TUBE pull-down
Endogenous polyUb conjugates were purified from primary fibrob-
lasts using TUBE affinity reagents as described previously
(Damgaard et al, 2012; Fiil et al, 2013). For further details, see
Appendix Supplementary Methods.
Ub chain composition analysis (AQUA-MS)
Details on LC-MS/MS methods for analysis of the cellular composi-
tion of Ub chain linkages can be found in Appendix Supplementary
Methods.
Immunoblotting
Samples were resolved on 4–12% Bis-Tris NuPAGE gels (Life Tech-
nologies) and transferred to nitrocellulose or polyvinylidene fluoride
(PVDF) membranes. Blots were visualised using ClarityTM Western
ECL Substrate (Bio-Rad) on a ChemiDocTM Touch or ChemiDocTM MP
imager (Bio-Rad). All antibodies are listed in Appendix Table S3.
Densitometry analysis of immunoblots was performed using the
Fiji software (Schindelin et al, 2012). For further details, see
Appendix Supplementary Methods.
ELISA
Cytokine and chemokine concentrations in cell culture medium were
measured using the Human IL-8/CXCL8 Quantikine ELISA kit
(D8000C) or the Human TNF-alpha Quantikine HS ELISA kit
(HSTA00E) from R&D Systems, Minneapolis, MN, according to the
manufacturer’s instructions. For IL-8 measurements, equal numbers
of primary fibroblasts from the OTULING281R patient or healthy
control were seeded in flat-bottom 96-well cell culture plates 24 h
before the experiments. Cells were washed, and fresh culture
medium was added immediately before the cells were treated with
10 ng/ml recombinant human TNF (Life Technologies) as indicated.
The cell culture medium was collected at the indicated times (for the
“0” samples, medium from untreated cells was left on the cells for
24 h and collected at the same time at the 24 h TNF-treated samples)
and subjected to ELISA analysis. For TNF measurements, equal
numbers of shControl and shOTULIN THP-1 cells were washed in
PBS and seeded in fresh medium in round-bottom 96-well plates.
The cells were then left untreated, and the culture medium was
collected at the indicated times and subjected to ELISA analysis.
MTT reduction assay for cell viability
MTT reduction assay was performed as previously described
(Damgaard et al, 2013) with cells treated with recombinant human
TNF (100 ng/ml; Life Technologies), ultrapure LPS from E. coli K12
(100 ng/ml; Invivogen), poly(I:C) (1 lg/ml; Invivogen), stau-
rosporine (1 lM; Sigma), cycloheximide (CHX; 50 lg/ml; Santa
Cruz Biotechnology), or a combination of recombinant human TNF
and CHX with or without the caspase inhibitor Q-VD-OPh (10 lM;
BioVision, Milpitas, CA) or the RIPK1 kinase inhibitor necrostatin-1
(Nec-1) (10 lM; Cayman Chemical, Ann Arbor, MI) as indicated.
For further details, see Appendix Supplementary Methods.
Histology, immunohistochemistry and TUNEL assay
Biopsies were fixed in formalin and embedded in paraffin before
sectioning and staining. Biopsies from patient III.2 were obtained
with informed consent (see below) from the pathological archives at
Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Healthy skin control biopsies were obtained from the Human
Research Tissue Bank, Cambridge Biomedical Research Centre,
Cambridge University Hospitals, UK. Deparaffinisation, haema-
toxylin and eosin (H&E) staining, cleaved caspase-3 immunohisto-
chemical staining (anti-cleaved caspase-3, #9661, RRID AB_2341188,
Cell Signaling Technology) with haematoxylin counterstaining, and
TUNEL assays (TdT In Situ Apoptosis Detection kit, #4810-30-K,
R&D Systems) with methyl green counterstaining were performed by
NDBbio Laboratories, LLC., Baltimore, MD. Stained slides were
scanned (20× objective), and image files (SVS files) were processed
using the QuPath software (https://qupath.github.io/; Bankhead
et al, 2017).
Statistics
Data are presented as mean  standard error of the mean (SEM) or
 standard deviation (SD) as indicated. Sample number (n) indi-
cates the number of independent biological samples in each experi-
ment. Sample numbers and experimental repeats are indicated in
figures and figure legends. Data were analysed using the two-way
analysis of variance (ANOVA) with Sidak’s correction for multiple
comparisons or the non-parametric Mann–Whitney U-test of the null
hypothesis as indicated. For the two-way ANOVA tests, the
Shapiro–Wilk test was used to assess normality of the data distribu-
tions. Generally, the datasets were normally distributed and as the
variables analysed (cytokine secretion and cell viability) are gener-
ally accepted to be normally distributed, the use of the two-way
ANOVA test was considered appropriate. Differences in means were
considered statistically significant at P < 0.05. Analyses were
performed using the GraphPad Prism software version 7.0b.
Study approval
Written informed consent was obtained from all subjects and family
members. The study was approved by the ethical committees of
Hadassah Medical Center and the Ministry of Health, Israel (Y.B),
and the South Birmingham Research Ethics Committee, UK
(E.R.M.), and performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki.
For additional methods and details, see Appendix Supplementary
Methods.
Data availability
Due to restrictions from the patient consent approved by the
research ethics committees, it is not be possible to deposit
complete exome sequencing data in a public repository, but the
data could be made available to interested researchers by contact-
ing the corresponding author (Y.B.). Accession numbers, coordi-
nates and structure factors for crystal structures of OTULING281R
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have been deposited within the protein data bank with accession
code 6I9C. Mass spectrometry data include global ubiquitin linkage
analysis by AQUA and been deposited to the Mass Spectrometry
Interactive Virtual Environment (MassIVE) (ftp://massive.ucsd.
edu/MSV000083154) at University of California San Diego, CA.
Expanded View for this article is available online.
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